Dai ichi Life Insurance Company Ltd Sells 10,200 Shares of Insulet Co. (NASDAQ:PODD)

Dai ichi Life Insurance Company Ltd decreased its position in Insulet Co. (NASDAQ:PODD) by 71.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,988 shares of the medical instruments supplier’s stock after selling 10,200 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Insulet were worth $928,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PODD. Tidal Investments LLC boosted its stake in Insulet by 58.8% in the 1st quarter. Tidal Investments LLC now owns 4,064 shares of the medical instruments supplier’s stock worth $697,000 after purchasing an additional 1,504 shares in the last quarter. iA Global Asset Management Inc. bought a new position in Insulet in the 1st quarter worth about $105,000. Swedbank AB bought a new position in Insulet in the 1st quarter worth about $6,903,000. Teachers Retirement System of The State of Kentucky boosted its stake in Insulet by 23.9% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 35,035 shares of the medical instruments supplier’s stock worth $6,006,000 after purchasing an additional 6,754 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale raised its position in Insulet by 7.1% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 11,607 shares of the medical instruments supplier’s stock worth $1,996,000 after buying an additional 770 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Citigroup boosted their target price on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Morgan Stanley boosted their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Raymond James boosted their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Finally, BTIG Research boosted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Stock Up 0.2 %

Shares of PODD opened at $266.92 on Friday. The firm has a market capitalization of $18.72 billion, a P/E ratio of 45.71, a P/E/G ratio of 4.08 and a beta of 1.22. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $279.40. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a fifty day moving average price of $243.21 and a 200-day moving average price of $212.74.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.